National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Sofosbuvir/velpatasvir (Epclusa®) for the treatment of chronic hepatitis C virus (HCV) infection in adults. This indication covers all genotypes (GT1, 2, 3, 4, 5 and 6) i.e. pangenotypic.

NCPE Rapid Review Process Complete
Rapid review received 05/09/2017
Rapid review completed 19/10/2017
Rapid Review outcome  Full pharmacoeconomic assessment not recommended